Update and developments in the treatment of glioblastoma multiforme – focus on bevacizumab

Naveed Wagle1
Leia Nghiemphu1
Albert Lai1
Whitney Pope2
Paul S Mischel3
Timothy Cloughesy1

1Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California; 2Department of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, California; 3Department of Pathology, David Geffen School of Medicine at UCLA, Los Angeles, California

Abstract: Glioblastoma is the most common primary brain tumor with a relatively poor prognosis. This article reviews the current standard therapy and discusses new developments in treatment of this disease. Surgical resection followed by radiation and chemotherapy has proven to be the most effective initial therapy. Recent advancement in molecular targeted therapies has led to the Food and Drug Administration (FDA) approval of bevacizumab in the setting of recurrent glioblastoma. The molecular pathways of glioblastoma growth are highlighted in this review. While numerous molecular targets are currently being intensely investigated, vascular endothelial growth factor (VEGF) receptor targeted therapy has been the only one to have shown clinical effect. The role of bevacizumab in this context provides a dynamic breakthrough in cancer therapy. Clinical trials have demonstrated significantly increased overall survival and six month progression free survival (PFS) in recurrent glioblastoma treated with bevacizumab alone or in combination with irinotecan. The use of this agent has also dramatically changed the imaging characteristics of glioblastoma. The anti-angiogenesis effects of bevacizumab have complicated the criterion for determining tumor growth. This may lead to redefinition of progressive disease based on non-invasive monitoring.

Keywords: glioblastoma, glioma, bevacizumab, vascular endothelial growth factor, avastin, angiogenesis, cancer

Introduction

Glioblastoma is the most common and aggressive primary brain tumor. The median life expectancy after diagnosis remains a mere 14 months. However, new advances have provided new optimism. The standard of care for treatment is resection followed by radiation with concurrent temozolomide.1 This regimen has had a significantly positive impact on progression free survival (PFS) and overall survival. Bevacizumab has recently received accelerated approval by the Food and Drug Administration (FDA) for the treatment of recurrent glioblastoma.

Chemotherapy has traditionally been targeted at inhibition of deoxyribonucleic acid (DNA) replication. This provided a non-specific mechanism by which to prevent cell growth. Our understanding of the pathways by which tumors are able to replicate and survive has expanded tremendously in recent years. This knowledge has shifted our experimental treatment strategy to specific molecular targeted therapies. Theoretically, individuals with aberrant signaling in one pathway are more likely to respond to agents that target those pathways than individuals with impairment in a different pathway. The focus has now shifted to intense research in clinical trials to find molecular targeted
agents that can benefit patients with glioblastoma.\(^2\)

Bevacizumab is a humanized monoclonal antibody against the vascular endothelial growth factor (VEGF).
The receptor for this ligand is involved in the mediation of vascular proliferation. It is known that one of the cardinal histologic features of glioblastoma is vascular proliferation. This allows the tumor to have a continued supply of nutrients allowing continued growth. Bevacizumab neutralizes the VEGF signaling pathway and thus prevents glioblastoma from increasing its vascular supply. This in turn will hamper further tumor growth.

**Standard therapy for glioblastoma**
The current standard therapy for glioblastoma is surgical resection followed by radiation therapy with concurrent temozolomide therapy. This is followed by adjuvant temozolomide therapy for at least six cycles of a 5 day on, 23 day off schedule. Overall survival with this regimen is 14.6 months with a median PFS of 6.9 months. Two year survival rates are 25.6%.\(^1\) The results show that glioblastoma is still a fatal disease with a poor prognosis. The treatment for recurrent glioblastoma has been an area in desperate need of advancement. Traditional chemotherapies have long been evaluated. The most commonly used therapies include carmustine, carboplatin, irinotecan, BCNU wafers, and repeat surgical intervention. Bevacizumab was recently approved by the FDA for use in this setting becoming the standard of care.

**Genetic variations in glioblastoma**
While there are many mutations that are likely to lead to the development of glioblastoma there are three main pathways activated in the majority of glioblastoma tumors. They can be best thought of as the epidermal receptor tyrosine kinase (EGFR), retinoblastoma (RB), and p53 pathways.\(^3\) Numerous clinical trials have attempted to target the components of these pathways but none have shown any clinical efficacy.\(^2\)

Given the lack of homogeneity in glioblastoma, the development of an effective targeted therapy has been challenging. Bevacizumab remains the only targeted agent which has significant response and clinical efficacy.

The EGFR is an upstream receptor that is activated by the binding of epidermal growth factor to the extracellular domain. In glioblastoma there is often a ligand-independent mutation of the receptor, called EGFRvIII, which is constitutively active.\(^4,10\) This results in recruitment of PI3K to the cell membrane. PI3K in turn phosphorylates phosphatidylinositol (PI)-4,5-bisphosphate to PI-3-phosphate (PIP3). This active enzyme activates downstream molecules such as protein kinase B (AKT) and mTOR.\(^14\) This signaling cascade leads to cell proliferation and inhibition of apoptosis. Phosphate and tensin homology (PTEN) is a checkpoint in this system which inhibits PIP3 signaling. PTEN is involved in regulating cell migration and invasion by directly dephosphorylating focal adhesion kinase. It also has homology to the catalytic region of protein tyrosine phosphates which is important to the function of PIP3. The PTEN gene is located at 10q23.3. There is a mutation of this gene in 15%–40% of glioblastomas suggesting that deregulation of this pathway is common in glioblastoma.\(^11,15,16\) Ras proteins are also stimulated by EGFR signal transduction. These membrane associated GTPases require post-translational addition of a farnesyl group to the C-terminus. This is accomplished by farnesyl transferase.\(^17\)

Once activated, Ras stimulates cellular proliferation, survival and angiogenesis.\(^18\)

The p53 pathway has been shown to have mutation in 87% of glioblastomas.\(^3\) This pathway is strongly implicated in glioblastoma that has transformed from a lower grade tumor. TP53 controls cell response to DNA damage by stimulating apoptosis or senescence. Mutation or homozygous deletion of this gene which is encoded at chromosome 17p13.1 can lead to disruption of this regulatory control.\(^19\) MDM2 binds TP53 and inhibits its ability to activate transcription of pro-moderator sequences.\(^20\) Amplification of MDM2 inhibits cells from entering apoptosis which can afford glioblastoma cells immortality. Upstream of MDM2 is the ARF gene product. The gene product binds to MDM2 and inhibits its ability to mediate p53 degradation and transactivational silencing.\(^21,23\)

Homozygous deletion or promoter methylation of this gene product leading to loss of expression has been found frequently in glioblastoma. Promoter methylation is more common in secondary glioblastoma but loss of expression is not significantly different between primary and secondary glioblastoma.\(^24\) Disruption of MDM2, TP53, or ARF can lead to loss of normal cell function due to autoregulatory feedback between these gene products.

The RB protein is involved in the progression of the cell through the cell cycle. Mutations in this pathway have been found in 78% of glioblastomas.\(^1\) The cell is inhibited from progressing from the G1 phase to the S phase by the RB protein. One mechanism by which this is done is inhibition of E2F transcription factor which activates the gene involved the transition between phases.\(^25\) The RB protein is phosphorylated by the CDK4/CCND2/CDK6 complexes which inhibits its activity. Amplification of these complexes
are observed in 1%–18% of glioblastomas. The downstream effect is to increase cell replication. Upstream of these complexes is p16 and CDKN2B which act to inhibit these complexes. Homozygous deletions in these genes are seen frequently in primary glioblastoma. Alteration in expression in any of these genes, RB, or CDK4 complexes can lead to uncontrolled cell division.

Angiogenesis is another target of molecular therapies. Glomeruloid vascular proliferation is feature manifested in nearly all glioblastomas. This is typically mediated through the VEGF receptor. The majority of signal transduction is through the VEGF receptor 2 (VEGFR-2). The role of VEGF receptor 1 remains unclear. While VEGF has a stronger affinity for this receptor, the signal transduction is rather weak. The agonists for the VEGF receptor are a family of structurally related molecules termed VEGF-A, VEGF-B, VEGF-C, and VEGF-D. The major mediator of tumor angiogenesis is VEGF-A which is typically referred to simply as VEGF. Many of the pathways used in the EGFR pathways are common to the VEGF signaling cascade thus blocking downstream may prevent angiogenesis as well. As the tumor grows it characteristically encounters impaired oxygenation and nutrients with toxic metabolite build up. Hypoxia, hypoglycemia and acidosis stimulate VEGF and other angiogenesis factors. The secreted VEGF binds to VEGFR-2 receptors which are expressed on endothelial cells. This suggests VEGF has both autocrine and paracrine mechanisms of action. Endothelial cell activation can lead to increased vascular permeability, vasorelaxation, endothelial cell migration, proliferation and survival. This stimulates new blood vessel formation from surrounding and existing vessels affording glioblastoma with neovascularature. Integrin mediated signaling and matrix metalloproteinases are also involved in angiogenesis. These proteins allow blood vessels to penetrate into surrounding tissue. Targeting the angiogenesis process to prevent tumor growth may occur anywhere from the signaling pathway, to the invasion mechanism, to the receptor level via antibodies. It is the latter target by which bevacizumab elicits its effect on angiogenesis.

**VEGF molecular targeted therapy**

The main focus of research in the treatment of glioblastoma has aimed its sights on molecular targeted therapies. We know that there may be subgroups of glioblastoma patients that respond to treatment with different results. This may be due to the variable molecular genetics present in glioblastoma cells that allow them to procreate aberrantly. While there are likely to be many pathways that may be involved the signaling cascade that allows tumor growth it may be that subgroups of patients have tumors with a dominant pathway. Theoretically, blocking this pathway in this group of patients would prevent tumor growth while it would not necessarily do this in a subgroup with a different dominant pathway. Glioblastoma, regardless of the cellular pathways driving its growth, is known to have increased VEGF production. VEGF allows glioblastoma to stimulate vascular proliferation in the surrounding area. This allows increased blood flow, nutrient supply, and oxygen delivery. All of these factors contribute to the ability of glioblastoma to survive and growth. It is been shown that high levels of VEGF in glioblastomas are associated with a poor prognosis.

When used with chemotherapy, bevacizumab has been associated with prolonged overall survival in metastatic colorectal and non-small-cell lung cancers. It has also been shown to have prolonged PFS when used with chemotherapy in metastatic breast and renal cancers. Just as it does in these cancers, bevacizumab works by the same mechanism of action in glioblastoma. The antibody binds the VEGF ligand and inhibits its ability to stimulate the signaling cascade which was previously described. Bevacizumab prevents secreted VEGF's from binding to their specific receptor thus disrupting activation of signaling cascades at the most upstream site. However, what is different in glioblastoma and renal cancer is that bevacizumab has benefits when used alone. This means that disruption of the VEGF pathway alone in glioblastoma is important for tumor control.

**Efficacy, safety and tolerability results**

In the recurrent glioblastoma setting the use of bevacizumab alone or in combination with irinotecan has been shown to be a viable therapy. The BRAIN study was a multi-center phase II randomized non-comparative open label trial of irinotecan and bevacizumab versus bevacizumab alone. The objective response rate is less than 10% and median overall survival is 30 weeks or less. The use of irinotecan as a single agent has a response rate of less than 15%. In the combination therapy there was a six month PFS of 50.3% and a median overall survival of 8.7 months. Median PFS has been reported as 5.6 months with an objective response rate of 37.8%. In the bevacizumab single agent arm six month PFS was 42.6% and median overall survival of 9.2 months. Median PFS has been reported as 10% and median overall survival is 30 weeks or less. The BRAIN study was a multi-center phase II randomized non-comparative open label trial of irinotecan and bevacizumab versus bevacizumab alone. The objective response rate is less than 10% and median overall survival is 30 weeks or less. The use of irinotecan as a single agent has a response rate of less than 15%. In the combination therapy there was a six month PFS of 50.3% and a median overall survival of 8.7 months. Median PFS has been reported as 5.6 months with an objective response rate of 37.8%. In the bevacizumab single agent arm six month PFS was 42.6% and median overall survival of 9.2 months. Median PFS has been reported as 10% and median overall survival is 30 weeks or less.
therapy for recurrent glioblastoma. These results showed that bevacizumab was effective in combination with irinotecan or as a single agent compared to historical controls in the setting of recurrent glioblastoma. It was based on these early results that bevacizumab gained accelerated FDA approval for treatment of recurrent glioblastoma.

The main side effects reported with bevacizumab single agent therapy were fatigue, headache, hypertension, and proteinuria. Far less common but significant side effects included arterial (2.4%) or venous thromboembolism (3.6%), impaired wound healing (2.4%), and intracranial hemorrhage, gastrointestinal perforation (1.3%) and posterior reversible leukoencephalopathy.

Recently bevacizumab has been evaluated in the upfront setting for newly diagnosed glioblastoma in a phase II study. This study has entered its expansion phase and may soon allow us to interpret the synergistic effect of bevacizumab with radiation and temozolomide in the upfront setting. Early results presented at the Society of Neuro-Oncology meeting in 2009 showed a median PFS of 14.1 months compared to historical controls of 6.9 months and institutional controls of 7.9 months. Survival data showed a median overall survival at 20.3 months in the treatment arm versus 14.6 months of the historical control and 21.1 months in the institutional control.51 Bevacizumab and temozolomide during and after radiation therapy was well-tolerated. The trial observed improved PFS but not overall survival compared to an internal control cohort. Additional studies are warranted to determine if bevacizumab administered upfront is superior to bevacizumab at recurrence.

**Imaging**

The anti-angiogenesis effect of bevacizumab has significant impact on the imaging characteristics of glioblastoma on magnetic resonance imaging (MRI). MRI is the main imaging modality for providing anatomic data on tumor size. The standard surrogate for tumor burden has been the change in contrast enhancement or a change in tumor size, edema and enhancement may be reduced significantly. It has been well documented that steroid requirements are reduced following bevacizumab therapy.44,56 This is thought to be due to reduced edema which can persist even with tumor progression.55 The clinical benefit of diminished edema and reduced steroid use has provided rationale for clinicians to continue bevacizumab therapy even with tumor progression. Preclinical data of bevacizumab treated rats having fewer symptoms despite larger tumor size then control rats, suggests that edema control has clinical benefit despite tumor progression.57 These anti-permeability effects, which are mediated through the VEGF pathway, have been seen in brain metastases from non-primary brain tumors as well.58,60

A concerning side effect seen in the pre-clinical setting of anti-angiogenesis therapy has been stimulated migration of glioblastoma cells.61,62 These findings have also been observed in trials of anti-angiogenesis agents in the clinical setting though not directly targeting VEGF.63 There have been trials showing that the use of bevacizumab in combination with other therapies to treat recurrent glioblastoma showed patterns of progression suggestive of a diffuse phenotype.64,65 However, analysis of the bevacizumab only arm in the BRAIN study showed no evidence of an increase in the diffuse phenotype.66 This may a significant effect on non-contrast MRI findings in this class of agents.

The assessment of the effect of bevacizumab based on Macdonald criteria becomes problematic, as it is unclear if the observed response is a change in contrast enhancement or a change in tumor burden. Tumor progression is typically noted due to an increase in contrast enhancement. Given impact of bevacizumab on vascular permeability and thus contrast enhancement, tumor progression following bevacizumab therapy manifests as T2/FLAIR signal changes not T1 post contrast enhancement.65 It has been shown that compared to the ease of identifying an enhancing tumor, a non-enhancing tumor is less easy to define.67 Increased non-enhancing tumor is not addressed when using Macdonald criteria for tumor progression. These changes can be difficult to differentiate from gliosis as a treatment reaction from surgery or radiation. These observations have lead to new recommendation for tumor assessment in neurooncology.42 Numerous MR techniques such as MR spectroscopy,68 MR perfusion,69 MR diffusion70 are being evaluated to help differentiate treatment related changes from tumor response. Metabolic imaging techniques with PET or SPECT have also been studied.71 Thus far, these techniques have not proved clinically effective.
At UCLA, we are investigating neutral amino acid imaging (FDOPA-PET) as a new biomarker for tumor burden which is not dependent on vascular permeability to provide a signal. The use of pretreatment apparent diffusion coefficient (ADC) histograms may also have a predictive role for bevacizumab responsive tumor.72

Conclusions
The treatment of glioblastoma continues to evolve. Further advances in molecular targeted therapies will hopefully allow individualized treatment based on specific tumor markers. Bevacizumab is the first FDA approved targeted therapy based on its efficacy in the treatment of recurrent glioblastoma. The front line therapy remains resection and subsequent temozolomide with radiation therapy followed by adjuvant temozolomide treatments. Bevacizumab is quickly becoming the first choice agent for use in the recurrent setting. Its use is associated with higher response rates, longer PFS and maintenance of quality of life. Bevacizumab as a targeted therapy represents the first step in a paradigm shift in the treatment of glioblastoma and cancer in general. Previous therapies have been aimed at non-specifically inhibiting cell division or growth. Molecular targeted therapy allows us to target specific pathways that are abnormally functioning. This practice requires an intimate knowledge of the aberrant molecular pathways involved in glioblastoma formation and growth. EGFR, RB, p53 signal pathways and angiogenesis are all area of future targets.

The effect on imaging is likely to be more profound than the actual effect on tumor burden. This leaves us with relatively impaired ability to evaluate further tumor growth with the traditional McDonald criteria. New methods for assessing non-contrast enhancing tumor are currently being evaluated. This may lead to new criteria by which the oncologist determines tumor progression. Bevacizumab has put us on the precipice of this change. Further research also needs to be done on predicting bevacizumab response based on imaging characteristics and molecular profiles.

Figure 1 T1 post-contrast imaging shows significant response to the enhancing tumor burden following bevacizumab therapy. The T2 imaging highlights the impact of edema with bevacizumab therapy with a significant decrease in the T2 hyperintensity.
Disclosures
The authors report no conflicts of interest in this work.

References


